SCYNEXIS Inc. (SCYX)

Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to b...

One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech ...

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks i...

Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential.

Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading a...

Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sal...

SAN DIEGO--(BUSINESS WIRE)---- $SCYX #SCYX--Scynexis, Inc. (SCYX) Misled Investors Regarding its Quality Control Measures.

NEW YORK--(BUSINESS WIRE)---- $SCYX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been fil...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 8, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who p...